The high mortality rate and increasing prevalence of resistant Mtb are the major concerns for the Tuberculosis (TB) treatment in this century. To curtail the prevalence of resistant Mtb, we have prepared 1,3-oxazine-2-one based dual targeted molecules. Compound 67 and 68 were found to be equally active against replicating and non-replicatiing form of Mtb (MIC_MABA 3.48 and 2.97 μg/ml; MIC_LORA 2.94 and 2.15 μg/ml respectively). They had found to suppress the biosynthesis of alfa, methoxy and keto-mycolate completely, as well as inhibit enzymatic activity of MenG (IC₅₀ = 9.11 and 6.25 μg/ml respectively for H37Ra; IC₅₀ = 11.76 and 10.88 μg/ml respectively for M smegmatis).

高死亡率和耐药性Mtb的流行是本世纪结核病（TB）治疗的主要问题。为了减少耐药性Mtb的流行，我们准备了基于1,3-恶嗪-2-一的双重靶向分子。发现化合物67和68对Mtb的复制和非复制形式具有同等活性（MIC _MABA 3.48和_2.97μg / ml； MIC _LORA分别为2.94和_2.15μg / ml）。他们已经发现抑制阿尔法生物合成，甲氧基和酮基mycolate完全，以及孟（IC的抑制酶活性₅₀  = 9.11和6.25微克/毫升分别杆菌H37Ra; IC ₅₀耻垢分枝杆菌 分别为11.76和10.88μg/ ml 。